DailyIQ
|
Sector:HealthcareAll sectors
Last updated 21 minutes ago

IQV·IQVIA Holdings Inc.

$.
+. (+.%)
After Hours
High
$211.87
Open
$207.98
Market Cap
34.60B
52W High
$247.05
Low
$201.40
P. Close
$206.87
P/E
24.98
52W Low
$154.50
Fwd P/E
14.81
DailyIQ Est.
$238.16
Technical Score (1D)
91
BUY
News Sentiment
50
MIXED
IQV is being evaluated against PEN, with analysts noting lower valuation multiples and a higher dividend yield, positioning IQV as a more attractive value play relative to PEN's higher volatility. Baird’s recent upgrade to a $252 price target from $249, while keeping an outperform rating, signals confidence in IQV’s projected revenue and margin expansion, suggesting the market expects continued earnings growth. Mizuho’s simultaneous lift of its target to $230 from $215, also maintaining an outperform stance, reinforces the consensus that IQV’s data‑analytics and cloud services are poised for market share gains. The company’s trailing 12‑month free cash flow margin of 12.7% underscores strong liquidity, which could support shareholder value if the firm deploys cash toward growth initiatives or share buybacks. Artisan Partners’ new long position, citing AI capabilities and resilience in clinical research, highlights investor optimism that AI integration will drive future revenue and operational efficiencies. With the Q2 2026 earnings release scheduled for July 28, traders should focus on management commentary for guidance on revenue mix, cost control, and AI‑driven product pipeline. ICON’s expansion into CRO services, aimed at capturing rising biopharma demand, could translate into higher contract volumes for IQV, potentially boosting top‑line growth. Evercore ISI, Argus, and HSBC all raised their price targets to $225, $235, and $240 respectively, reflecting a broader bullish consensus on IQV’s earnings trajectory amid a favorable macro environment for health‑tech solutions. Upcoming earnings and any new partnership or regulatory developments will be key watch items, as they will confirm whether the company can sustain the upward price target revisions and capitalize on its AI and CRO momentum.
Earnings Summary
IQVIA Holdings, Inc. is a global provider of technology, analytics, and services that support the life sciences and healthcare industries. The company’s integrated offerings span three primary segments—Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions—enabling clients to access clinical trial support, data‑driven insights, and commercialization strategies across pharmaceutical, biotechnology, and medical device markets. In recent quarters, IQVIA’s financial performance has been consistently strong: Q4 2024 delivered an EPS of $3.12 versus an estimate of $3.10883, with revenue of $3.958 billion; Q1 2025 reported $2.70 EPS against $2.63225 expected, revenue $3.829 billion; Q2 2025 posted $2.81 EPS versus $2.77039 forecast, revenue $4.017 billion; Q3 2025 achieved $3.00 EPS against $2.97588 estimate, revenue $4.100 billion; Q1 2026 recorded $2.90 EPS versus $3.04243 forecast, revenue $4.151 billion, with Q2 2026 results pending. Revenue has grown from $3.958 billion to $4.151 billion, consistently beating analyst estimates, while EPS has largely outperformed expectations except for the most recent quarter. Analyst sentiment has been bullish, with Baird raising the price target to $252 and Mizuho to $230, reflecting confidence in revenue and margin expansion; Artisan Partners opened a new long position citing AI capabilities, and the company’s trailing 12‑month free‑cash‑flow margin of 12.7 % underscores solid liquidity. The parent company ICON is expanding into CRO services, potentially broadening IQVIA’s revenue base, and the upcoming Q2 2026 earnings release on July 28 will be a key event for guidance on revenue mix, cost control, AI‑driven product pipeline, and partnership developments. Investors should monitor the earnings call for updates on cash utilization, regulatory changes, and any new partnership announcements that could influence the company’s growth trajectory.

EPS

EstBeatMiss
$2.56$2.72$2.88$3.03$3.19Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.03 - -
Q1'26$3.04$2.90-4.7%
Q3'25$2.98$3.00+0.8%
Q2'25$2.77$2.81+1.4%
Q1'25$2.63$2.70+2.6%
Q4'24$3.11$3.12+0.4%

Revenue

EstBeatMiss
$3.8B$3.9B$4.1B$4.3B$4.4BQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.3B - -
Q1'26$4.2B$4.2B-2.3%
Q3'25 - $4.1B -
Q2'25 - $4.0B -
Q1'25 - $3.8B -
Q4'24 - $4.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

IQV Stock Snapshot

IQV is currently trading at $206.81, giving IQVIA Holdings Inc. a market cap of 34.60B and a P/E ratio of 25.0. Today's range spans $201.40–$211.87, with shares opening at $207.98 and moving down $0.06 (0.0%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 50/100.

Over the past year IQV has traded between $154.50 and $247.05 - the current price is +33.9% off the 52-week low and -16.3% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $230.42 (range $200.00–$284.00), implying upside of +11.4%.

IQV is showing the kind of bullish setup that active managers add to on dips - 91/100 (BUY), neutral sentiment at 50/100, 34.60B market cap in Healthcare, price $206.81 (in the middle of its 52-week range). The current P/E ratio stands at 25.0. At this cap tier, the combination of technical confirmation and positive sentiment is what separates speculative bullish positions from high-conviction ones. Annual range: $154.50–$247.05. The setup is in the latter category.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (91/100) and news sentiment (50/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $206.81 (in the middle of its 52-week range), IQV's position within the $154.50–$247.05 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.